HDAC Inhibitor L-Carnitine and Proteasome Inhibitor Bortezomib Synergistically Exert Anti-Tumor Activity In Vitro and In Vivo

Combinations of proteasome inhibitors and histone deacetylases (HDAC) inhibitors appear to be the most potent to produce synergistic cytotoxicity in preclinical trials. We have recently confirmed that L-carnitine (LC) is an endogenous HDAC inhibitor. In the current study, the anti-tumor effect of LC...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Huang, Hongbiao, Liu, Ningning, Yang, Changshan, Liao, Siyan, Guo, Haiping, Zhao, Kai, Li, Xiaofen, Liu, Shouting, Guan, Lixia, Liu, Chunjiao, Xu, Li, Zhang, Change, Song, Wenbin, Li, Bing, Tang, Ping, Dou, Q. Ping, Liu, Jinbao
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2012
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3527572/
https://ncbi.nlm.nih.gov/pubmed/23285100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0052576
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados